|
WO2021051135A1
|
|
Pikfyve inhibitors for cancer therapy
|
|
US2021073648A1
|
|
Techniques for semi-supervised training and associated applications
|
|
TW202045165A
|
|
Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
|
|
BR112020016256A2
|
|
COMBINATION THERAPY WITH APILIMOD AND GLUTEN-MATERIAL AGENTS
|
|
WO2019067666A1
|
|
Therapeutic methods relating to hsp90 inhibitors
|
|
US2018200184A1
|
|
Rapamycin for the treatment of lymphangioleiomyomatosis
|
|
AU2017342262A1
|
|
Apilimod compositions and methods for using same in the treatment of alzheimer's disease
|
|
CN109952113A
|
|
Composition comprising PIKFYVE inhibitor and method relevant to the inhibition of RANK signal transduction
|
|
US2018028540A1
|
|
Anti-viral compositions containing PIKfyve inhibitors and use thereof
|
|
AU2015240485A1
|
|
An inhalable rapamycin formulation for treating age-related conditions
|
